Shares of Pain Therapeutics Inc. fell 18% Tuesday after the company released a statement railing against the U.S. Food and Drug Administration’s refusal to approve drug candidate Remoxy.

from MarketWatch.com - Top Stories https://on.mktw.net/2TA8j6g
via IFTTT
from MarketWatch.com - Top Stories https://on.mktw.net/2TA8j6g
via IFTTT
Kommentare
Kommentar veröffentlichen